Advertisement

Immunosuppressive Strategies to Improve Outcomes of Kidney Transplantation

      Summary

      The introduction of several immunosuppressive agents over the past decade has reduced the rate of acute rejection significantly and has improved short-term renal allograft survival. However, their impact on long-term outcomes remains unclear. Current immunosuppressive strategies are focused on improving long-term graft and patient survival along with maintaining allograft function. The approval of the new immunosuppressive agents: rabbit antithymocyte globulin, basiliximab, daclizumab, tacrolimus, mycophenolate, and sirolimus, also has facilitated the development of steroid- and calcineurin inhibitor–sparing regimens in kidney transplantation. We discuss the impact of various immunosuppressive regimens on the outcome measures of kidney transplantation: acute rejection episodes, allograft survival, and renal function.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Seminars in Nephrology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Meier-Kriesche H.-U.
        • Schold J.D.
        • Srinivas T.R.
        • et al.
        Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era.
        Am J Transplant. 2004; 4: 378-383
        • Gourishankar S.
        • Hunsicker L.G.
        • Ihangri G.S.
        • et al.
        The stability of the GFR after renal transplantation is improving.
        J Am Soc Nephrol. 2003; 14: 2387-2394
        • Kasiske B.L.
        • Gaston R.S.
        • Gourishankar S.
        • et al.
        Long-term deterioration of kidney allograft function.
        Am J Transplant. 2005; 5: 1405-1414
        • Keith D.S.
        • DeMattos A.
        • Golconda M.
        • et al.
        Factors associated with improvement in deceased donor renal allograft function in the 1990s.
        J Am Soc Nephrol. 2005; 16: 1512-1521
        • Meier-Kriesche H.-U.
        • Schold J.D.
        • Kaplan B.
        Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies?.
        Am J Transplant. 2004; 4: 1289-1295
        • Vincenti F.
        • de Andres A.
        • Becker T.
        • et al.
        Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients.
        Transpl Int. 2006; 19: 446-457
        • Mourad G.
        • Garrigue V.
        • Squifflet J.-P.
        • et al.
        Induction versus non-induction in renal transplant recipients with tacrolimus-based immunosuppression.
        Transplantation. 2001; 72: 1050-1055
        • Hardinger K.L.
        • Schnitzler M.A.
        • Miller B.
        • et al.
        Five-year follow up of rabbit ATG versus ATGAM induction in adult renal transplantation.
        Transplantation. 2004; 78: 136-141
        • Nashan B.
        • Moore R.
        • Amlot P.
        • et al.
        • CHIB 201 International Study Group
        Randomized trial of basiliximab versus placebo for control of cellular rejection in renal allograft recipients.
        Lancet. 1997; 350: 1193-1198
        • Kahan B.D.
        • Rajagopalan P.R.
        • Hall M.
        • United States Simulect Renal Study Group
        Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody.
        Transplantation. 1999; 7: 276-284
        • Pontecelli G.
        • Yussim A.
        • Cambi V.
        • et al.
        A randomized double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients.
        Transplantation. 2001; 72: 1261-1267
        • Lawen J.G.
        • Davies E.A.
        • Mourad G.
        • et al.
        Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation.
        Transplantation. 2003; 75: 37-43
        • Vincenti F.
        • Kirkman R.
        • Light S.
        • et al.
        Interleukin-2 receptor blockade with daclizumab to prevent acute rejection in renal transplantation.
        N Engl J Med. 1998; 338: 161-165
        • Nashan B.
        • Light S.
        • Hardie I.
        • et al.
        Reduction of acute renal allograft rejection by daclizumab: Daclizumab Double Therapy Study Group.
        Transplantation. 1999; 67: 110-115
        • Adu D.
        • Cockwell P.
        • Ives N.J.
        • et al.
        Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomized trials.
        BMJ. 2003; 326: 789-793
        • Mourad G.
        • Rostaing L.
        • Legendre C.
        • et al.
        Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids.
        Transplantation. 2004; 78: 584-590
        • Lecranchu Y.
        • Bridoux F.
        • Buchler M.
        • et al.
        Immunoprophylaxis with basiliximab compared with antithymocyte globulin for prevention of acute renal allograft rejection.
        Am J Transplant. 2002; 2: 48-51
        • Sollinger H.
        • Kaplan B.
        • Pescovitz M.D.
        • et al.
        Basiliximab versus antithymocyte globulin for prevention of acuter renal allograft rejection.
        Transplantation. 2001; 72: 1915-1919
        • Brennan D.C.
        • Daller J.A.
        • Lake K.D.
        • et al.
        Rabbit antithymocyte globulin versus basiliximab in renal transplantation.
        N Engl J Med. 2006; 355: 1967-1977
        • Haririan A.
        • Morawski K.
        • Sillix D.H.
        • et al.
        Induction therapy with basiliximab versus rabbit ATG in African-American kidney transplant recipients.
        Transplantation. 2005; 79: 716-721
        • Ciancio G.
        • Burke G.W.
        • Gaynor J.J.
        • et al.
        A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing and newer immune-monitoring.
        Transplantation. 2005; 80: 457-465
        • Meier-Kriesche H.-U.
        • Li S.
        • Grussner R.W.G.
        • et al.
        Immunosuppression: evolution in practice and trends 1994-2004.
        Am J Transplant. 2006; 6: 1111-1131
        • Kramer B.K.
        • Montagnino G.
        • Del Castillo D.
        • et al.
        Efficacy and safety of tacrolimus compared with cyclosporine A microemulsion in renal transplantation: 2 year follow-up results.
        Nephrol Dial Transplant. 2005; 20: 968-973
        • Vincenti F.
        • Jensik S.G.
        • Filo R.S.
        • et al.
        A long-term comparison of tacrolimus (FK 506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at 5 years.
        Transplantation. 2002; 73: 775-782
        • Johnson C.
        • Ahsan N.
        • Gonwa T.
        • et al.
        Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil after cadaveric kidney transplantation.
        Transplantation. 2000; 69: 834-841
        • Ahsan N.
        • Johnson C.
        • Gonwa T.
        • et al.
        Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years.
        Transplantation. 2001; 72: 245-250
        • Gonwa T.
        • Johnson C.
        • Ahsan N.
        • et al.
        Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years.
        Transplantation. 2003; 75: 2048-2053
        • Kaplan B.
        • Schold J.D.
        • Meier-Kriesche H.U.
        Long-term graft survival with Neoral and tacrolimus: a paired kidney analysis.
        J Am Soc Nephrol. 2003; 14: 2980-2984
        • European Mycophenolate Mofetil Cooperative Study Group
        Placebo controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection.
        Lancet. 1995; 345: 1321-1325
        • Sollinger H.W.
        • U.S. Renal Transplant Mycophenolate Mofetil Study Group
        Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients.
        Transplantation. 1995; 60: 225-232
        • Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group
        A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation.
        Transplantation. 1996; 61: 1029-1037
        • Halloran P.
        • Mathew T.
        • Tomlanovic S.
        • et al.
        • The International Mycophenolate Mofetil Renal transplant Study Groups
        Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection.
        Transplantation. 1997; 63: 39-47
        • European Mycophenolate Mofetil Cooperative Study Group
        Mycophenolate mofetil on renal transplantation: 3-year results from the placebo-controlled trial.
        Transplantation. 1999; 68: 391-396
        • Mathew T.H.
        • Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group
        A blinded, long-term, randomized multi-center study of mycophenolate mofetil in cadaveric renal transplantation: results at three years.
        Transplantation. 1998; 65: 1450-1454
        • Ojo A.O.
        • Meier-Kriesche H.-U.
        • Hanson J.A.
        • et al.
        Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection.
        Transplantation. 2000; 69: 2405-2409
        • Meier-Kriesche H.-U.
        • Ojo A.O.
        • Leichtman A.B.
        • et al.
        Effect of mycophenolate mofetil on long-term outcomes in African-American renal transplant recipients.
        J Am Soc Nephrol. 2000; 11: 2366-2370
        • MacDonald A.S.
        • Rapamune Global Study Group
        A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts.
        Transplantation. 2001; 71: 271-280
        • Kahan B.D.
        • Rapamune US Study Group
        Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomized multicentre study.
        Lancet. 2000; 356: 194-202
        • Mendez R.
        • Gonwa T.
        • Yang H.C.
        • et al.
        A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year.
        Transplantation. 2005; 80: 303-309
        • Meier-Kriesche H.-U.
        • Steffen B.J.
        • Chu A.H.
        • et al.
        Sirolimus with Neoral versus mycophenolate mofetil with Neoral is associated with decreased renal allograft survival.
        Am J Transplant. 2004; 4 (2058-20)
        • Meier-Kriesche H.-U.
        • Schold J.D.
        • Srinivas T.R.
        • et al.
        Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus.
        Am J Transplant. 2005; 5: 2273-2280
        • Grinyó J.M.
        Steroid sparing strategies in renal transplantation.
        Nephrol Dial Transplant. 2005; 20: 2028-2031
        • Opelz G.
        • Dohler B.
        • Laux G.
        Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients.
        Am J Transplant. 2005; 5: 720-728
        • Vanrenterghem Y.
        • van Hooff J.P.
        • Squifflet J.P.
        • et al.
        Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial.
        Am J Transplant. 2005; 5: 87-95
        • Vincenti F.
        • Monaco A.
        • Grinyó J.
        • et al.
        Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil.
        Am J Transplant. 2003; 3: 306-311
        • Rostaing L.
        • Cantarovich D.
        • Mourad G.
        • et al.
        Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation.
        Transplantation. 2005; 79: 807-814
        • Matas A.J.
        • Ramcharan T.
        • Paraskevas S.
        • et al.
        Rapid discontinuation of steroids in living donor kidney transplantation: a pilot study.
        Am J Transplant. 2001; 1: 278-283
        • Khwaja K.
        • Asolati M.
        • Harmon J.
        • et al.
        Outcome at 3 years with a prednisone-free maintenance regimen: a single-center experience with 349 kidney transplant recipients.
        Am J Transplant. 2004; 4: 980-987
        • Khwaja K.
        • Asolati M.
        • Harmon J.V.
        • et al.
        Rapid discontinuation of prednisone in higher-risk kidney transplant recipients.
        Transplantation. 2004; 78: 1397-1399
        • Kandaswamy R.
        • Melancon J.K.
        • Dunn T.
        • et al.
        A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients—an interim analysis.
        Am J Transplant. 2005; 5: 1529-1536
        • Matas A.J.
        • Kandaswamy R.
        • Gillingham K.J.
        • et al.
        Prednisone-free maintenance immunosuppression—a 5-year experience.
        Am J Transplant. 2005; 5: 2473-2478
        • Kumar M.S.A.
        • Moritz M.J.
        • Saaed M.I.
        • et al.
        Avoidance of chronic steroid therapy in African American kidney transplant recipients monitored by surveillance biopsy: 1-year results.
        Am J Transplant. 2005; 5: 1976-1985
        • Kumar M.S.A.
        • Heifets M.
        • Moritz M.J.
        • et al.
        Safety and efficacy of steroid withdrawal two days after kidney transplantation: analysis of results at three years.
        Transplantation. 2006; 81: 832-839
        • Smak Gregoor P.J.H.
        • DeSevaux R.L.
        • Ligtenberg G.
        • et al.
        Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study.
        J Am Soc Nephrol. 2002; 13: 1365-1373
        • Hazzan M.
        • Buob D.
        • Labalette M.
        • et al.
        Assessment of the risk of chronic allograft dysfunction after renal transplantation in a randomized cyclosporine withdrawal trial.
        Transplantation. 2006; 82: 657-662
        • Schnuelle P.
        • van der Heide J.H.
        • Tegzess A.
        • et al.
        Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen.
        J Am Soc Nephrol. 2002; 13: 536-543
        • Abramowicz D.
        • Del Carmen Rial M.
        • Vitko S.
        • et al.
        Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study.
        J Am Soc Nephrol. 2005; 16: 2234-2240
        • Nashan B.
        • Eldberg H.
        • Grinyó J.
        • et al.
        Cyclosporine sparing with the use of mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients- the CAESAR Study 36 month results.
        Am J Transplant. 2006; 6: 436
        • Johnson R.W.G.
        • Kreis H.
        • Oberbauer R.
        • et al.
        Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure.
        Transplantation. 2001; 72: 777-786
        • Oberbauer R.
        • Kreis H.
        • Johnson R.W.G.
        • et al.
        Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune maintenance regimen study.
        Transplantation. 2003; 76: 364-370
        • Kreis H.
        • Oberbauer R.
        • Campistol J.M.
        • et al.
        Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal.
        J Am Soc Nephrol. 2004; 15: 809-817
        • Mota A.
        • Arias M.
        • Taskinen E.I.
        • et al.
        Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years.
        Am J Transplant. 2004; 4: 953-961
        • Oberbauer R.
        • Segoloni G.
        • Campistol J.M.
        • et al.
        Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation.
        Transpl Int. 2005; 18: 22-28
        • Vincenti F.
        • Ramos E.
        • Brattstrom C.
        • et al.
        Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation.
        Transplantation. 2001; 71: 1282-1287
        • Grinyó J.M.
        • Gil-Vernet S.
        • Cruzado J.M.
        • et al.
        Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.
        Transpl Int. 2003; 16: 820-827
        • Flechner S.M.
        • Goldfarb D.
        • Modlin C.
        • et al.
        Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine.
        Transplantation. 2002; 74: 1070-1076
        • Flechner S.M.
        • Kurian S.M.
        • Solez K.
        • et al.
        De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years.
        Am J Transplant. 2004; 4: 1776-1785
        • Flechner S.M.
        • Goldfarb D.
        • Solez K.
        • et al.
        Kidney transplantation with sirolimus and mycophenolate mofetil based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs.
        Transplantation. 2007; 83: 883-892
        • Grinyó J.M.
        • Cruzado J.M.
        Mycophenolate mofetil and sirolimus combination in renal transplantation.
        Am J Transplant. 2006; 6: 1991-1999
        • Ciancio G.
        • Burke G.W.
        • Gaynor J.J.
        • et al.
        A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (Neoral) and sirolimus in renal transplantation.
        Transplantation. 2004; 77: 244-251
        • Ciancio G.
        • Burke G.W.
        • Gaynor J.J.
        • et al.
        A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (Neoral)/sirolimus in renal transplantation.
        Transplantation. 2004; 77: 252-258
        • Gonwa T.
        • Mendez R.
        • Yang H.C.
        • et al.
        • Prograf Study Group
        Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months.
        Transplantation. 2003; 75: 1213-1220
        • Mendez R.
        • Gonwa T.
        • Yang H.C.
        • et al.
        A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year.
        Transplantation. 2005; 80: 303-309
        • Vitko S.
        • Wlodarczyk Z.
        • Kyllonen L.
        • et al.
        Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study.
        Am J Transplant. 2006; 6: 531-538
        • Gallon L.
        • Perico N.
        • Dimitrov B.D.
        • et al.
        Long-term renal allograft function on a tacrolimus-based, pred-free maintenance immunosuppression comparing sirolimus vs. MMF.
        Am J Transplant. 2006; 6: 1617-1623
        • Larson T.S.
        • Dean P.G.
        • Stegall M.D.
        • et al.
        Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus.
        Am J Transplant. 2006; 6: 514-522
        • Ekberg H.
        • Tedesco-Silva H.
        • Demirbas A.
        • et al.
        SYMPHONY-comparing standard immunosuppression to low-dose cyclosporine, tacrolimus, or sirolimus in combination with mycophenolate mofetil, daclizumab and corticosteroids in renal transplantation.
        Am J Transplant. 2006; : 83
        • Ekberg H.
        • Ginyo Josep
        • Nashan B.
        • et al.
        Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study.
        Am J Transplant. 2007; 7: 560-567
        • Nankwell B.J.
        • Gruenewald S.M.
        • Allen R.D.M.
        • et al.
        Predicting glomerular filtration rate after kidney transplantation.
        Transplantation. 1995; 59: 683-689
        • Cockroft D.W.
        • Gault M.H.
        Prediction of creatinine clearance from serum creatinine.
        Nephron. 1976; 16: 31-41
        • Gaspari F.
        • Ferrari S.
        • Stucchi N.
        • et al.
        Performance of different prediction equations for estimating renal function in kidney transplantation.
        Am J Transplant. 2004; 4: 1826-1835